Early Use of Automated Insulin Delivery With Telehealth Support in People Recently Diagnosed With Type 1 Diabetes: One‐Year Outcomes From a Prospective Observational Study
- 17 September 2026
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (12) , 11545-11555
Abstract
Aims: This study aims to evaluate the effectiveness and safety of early AID initiation combined with a telehealth support programme in individuals recently diagnosed with type 1 diabetes (T1D) in mainland China. Materials and Methods: This prospective, single‐arm, observational study sequentially enrolled individuals within 3 months of T1D diagnosis who initiated self‐funded AID system with the AndroidAPS algorithm. Participants received a structured e‐learning and personalised telehealth consultation during the first month followed by regular virtual follow‐up. Glycaemic outcomes were assessed at 1, 3, 6, and 12 months after AID initiation. Safety outcomes included severe hypoglycaemia (SH) and diabetic ketoacidosis (DKA). Results: A total of 126 participants completed at least 3 months of follow‐up. Median age was 13.6 (8.9, 27.4) years and median diabetes duration was 0.9 (0.5, 1.7) months. Percentage of time in range 3.9–10.0 mmol/L (TIR) was 85.2% (80.4, 90.7) during the first month and remained stable through 12 months. Among individuals with prior CGM data ( N = 93), TIR increased from 70.0% (58.6, 80.2) before AID initiation to 84.8% (79.9, 90.4) at 1 month and remained similar at 12 months. HbA1c (when available, n = 95) decreased from 10.0% (8.0, 13.4) [86 mmol/mol (64, 123)] at diagnosis to 6.3% (6.0, 6.8) [45 mmol/mol (42, 51)] at 12 months. No episodes of SH or DKA were reported. However, by the latest data update (August, 2026), the AID discontinuation rate was 35.7% ( N = 45), which was mainly due to financial barriers (55.2%). Conclusions: Early self‐funded AID initiation, supported by telehealth support, was associated with rapid and sustained glycaemic improvement in those recently diagnosed with T1D. Financial burden was the key challenge for consistent use of this advanced diabetes technology. Trail Registration: NCT06081231.Keywords
This publication has 19 references indexed in Scilit:
- Real-world efficacy and safety of open-source automated insulin delivery for people with type 1 diabetes mellitus: Experience from mainland ChinaDiabetes Research and Clinical Practice, 2024
- Do-It-Yourself Automated Insulin Delivery: A Health-care Practitioner User’s GuideCanadian Journal of Diabetes, 2023
- Effect of Tight Glycemic Control on Pancreatic Beta Cell Function in Newly Diagnosed Pediatric Type 1 DiabetesJAMA, 2023
- Barriers to uptake of Open-Source automated insulin delivery Systems: Analysis of socioeconomic factors and perceived challenges of adults with type 1 diabetes from the OPEN surveyDiabetes Research and Clinical Practice, 2022
- Open-Source Automated Insulin Delivery in Type 1 DiabetesNew England Journal of Medicine, 2022
- Closed-Loop Therapy and Preservation of C-Peptide Secretion in Type 1 DiabetesNew England Journal of Medicine, 2022
- What Training, Support, and Resourcing Do Health Professionals Need to Support People Using a Closed-Loop System? A Qualitative Interview Study with Health Professionals Involved in the Closed Loop from Onset in Type 1 Diabetes (CLOuD) TrialDiabetes Technology & Therapeutics, 2020
- The remission phase in type 1 diabetes: Changing epidemiology, definitions, and emerging immuno‐metabolic mechanismsDiabetes/Metabolism Research and Reviews, 2019
- The Relationship of Hemoglobin A1C to Time-in-Range in Patients with DiabetesDiabetes Technology & Therapeutics, 2019
- Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 DiabetesNew England Journal of Medicine, 2005